Verubecestat
Verubecestat is an experimental drug developed for the treatment of Alzheimer's disease. It is a BACE1 inhibitor, which means it works by blocking the action of an enzyme called beta-secretase 1 that is involved in the production of a protein called beta-amyloid. Beta-amyloid is a key component of the plaques that form in the brains of people with Alzheimer's disease.
Development and Clinical Trials[edit | edit source]
Verubecestat was developed by Merck & Co., a multinational pharmaceutical company. The drug entered Phase III clinical trials in 2015, making it the first BACE1 inhibitor to reach this stage of development. However, in 2018, Merck announced that it was discontinuing these trials because an interim analysis showed that the drug was unlikely to show a positive benefit-risk ratio.
The failure of Verubecestat in clinical trials was a significant setback for the development of BACE1 inhibitors as a treatment for Alzheimer's disease. However, it also provided valuable information about the role of beta-amyloid in the disease and the potential risks and benefits of targeting this protein.
Mechanism of Action[edit | edit source]
Verubecestat works by inhibiting the action of BACE1, an enzyme that plays a key role in the production of beta-amyloid. By blocking this enzyme, the drug reduces the levels of beta-amyloid in the brain. This is thought to slow the progression of Alzheimer's disease by preventing the formation of plaques.
However, the clinical trials of Verubecestat showed that this approach may not be effective. This has led to a re-evaluation of the role of beta-amyloid in Alzheimer's disease and the potential benefits of targeting this protein.
Future Research[edit | edit source]
Despite the failure of Verubecestat in clinical trials, research into BACE1 inhibitors and other approaches to reducing beta-amyloid levels continues. It is hoped that this research will lead to the development of more effective treatments for Alzheimer's disease in the future.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
